The Funnels Guys Unveil New DFY GHL Systems for 2026

London, UK -  TheFunnelsGuys.com, one of the fastest-growing GoHighLevel implementation teams in the UK, today announced the expansion of its end-to-end CRM, automation, and funnel-building services designed to help businesses streamline operations, boost lead conversions, and scale revenue with precision.

Founded by long-time marketers and certified GoHighLevel specialists, The Funnels Guys have quickly become a go-to authority for businesses seeking high-performing sales funnels, AI-powered automation, and complete CRM system builds without the high agency overhead.

“Businesses know they need automation, but they don’t want to spend months figuring out the tech,” said Cormac Reynolds, Co-Founder of The Funnels Guys. “Our job is simple: build systems that generate leads, nurture them automatically, and plug revenue leaks — all inside one unified GoHighLevel setup.”

A Full-Stack GoHighLevel Implementation Team

The Funnels Guys provide a comprehensive suite of services, including:

• Custom GoHighLevel CRM Builds
• High-Converting Sales Funnels & Landing Pages
• AI-Driven Chatbots & Automation Workflows
• Pipeline Setup, Follow-Up Sequences & Review Campaigns
• Industry-Specific Snapshots for Real Estate, Coaches, Agencies, Service Businesses & More
• Ongoing System Maintenance & Optimisation

Unlike traditional marketing agencies, The Funnels Guys combine strategic funnel design with technical GoHighLevel mastery, allowing businesses to launch complete marketing and sales engines in weeks — not months.

Recent Growth and Expanding Client Base

Over the last year, the company has onboarded clients across the UK, US, and Europe, serving industries such as:

• Real Estate
• Coaching & Consulting
• Finance (Mortgage Brokers, Advisors, Insurance)
• Trades & Local Services
• Ecommerce
• Agencies
• Healthcare & Wellness

This growth has also been supported by the relaunch of GoHighLevelStudio.com, the company’s official case-study hub showcasing real-world builds, before-and-after funnels, and success stories.

Raising the Standard of GHL Implementation

Businesses often struggle with freelancers providing partial builds or unfinished systems. The Funnels Guys aim to redefine what done-for-you should mean in the GoHighLevel ecosystem.

“We’ve seen too many businesses paying for sloppy setups,” said Khyatt, Lead Architect at The Funnels Guys. “We focus on clarity, communication, and systems that actually work out of the box. No fluff. No shortcuts.”

Looking Ahead

The company is also preparing to launch:

• Industry-specific ready-to-deploy snapshots
• AI-powered follow-up engines
• Turnkey lead-generation funnels
• White-label solutions for agencies

With increasing demand for automation and CRM consolidation, The Funnels Guys expect continued expansion throughout 2026.

For more details contact The Funnels Guys – Press Office at support@thefunnelsguys.com

Learn more at: http://thefunnelsguys.com/

About The Funnels Guys

TheFunnelsGuys.com is a UK-based GoHighLevel implementation and automation agency specialising in done-for-you systems, funnels, and CRM architecture. The company helps businesses streamline operations, improve conversions, and scale through automation — all within a single, unified GoHighLevel ecosystem.

Media Contact
Company Name: The Funnels Guys
Contact Person: Cormac Reynolds
Email:Send Email
City: London
Country: United Kingdom
Website: TheFunnelsGuys.com

The Malaysia Harrell Foundation Hosts Transformational "Align & Rise" Retreat Honoring Veterans and Their Families

Malaysia Harrell is the founder of The Malaysia Harrell Foundation and Blissful Life Consulting.

Annapolis, MD - The Malaysia Harrell Foundation successfully hosted its inaugural Align & Rise Wellness Retreat during Veterans Day week from November 10-12, 2025, at the peaceful Moonstone Escape in Massanutten, Virginia. This intimate luxury retreat was intentionally created to honor and celebrate Veteran women and Veteran spouses in recognition of Veterans Day, offering a sacred environment for rest, renewal, and reflection.

Guided by the visionary leadership of Malaysia Harrell, LICSW, LCSW-C, BCD, psychotherapist, U.S. Air Force Veteran, and founder of The Malaysia Harrell Foundation and Blissful Life Consulting, the Align & Rise Retreat served as a soul-centered experience rooted in holistic healing, empowerment, and gratitude. A small group of women gathered for a deeply transformational weekend focused on restoration, purpose, and self-discovery.

“This gathering was more than a retreat; it was truly a homecoming,” said Harrell. “Our Veterans and their families give so much of themselves in service to others. Align & Rise was created as a space to give back, a place to breathe, heal, and remember they deserve to be poured into as well.”

A Sacred Three-Day Experience of Healing and Restoration

Over the course of three days, participants were immersed in a blend of mindfulness, reflection, and community, complemented by luxurious wellness experiences designed to nurture mind, body, and spirit. Experiences included:

• Morning stillness and guided meditation in nature
• Transformational soul-healing sessions led by Malaysia Harrell
• Nourishing meals prepared by private chef Julie Alexandra
• Restorative massage therapy and integrative energy healing
• Fireside conversations fostering vulnerability, sisterhood, and deep connection

The retreat concluded with a powerful reflection circle, where participants shared stories of resilience, renewal, and the sacred practice of choosing themselves again.

A Journey Into Nature and Renewal

On Day Two, participants visited the tranquil White Oak Lavender Farm in the Shenandoah Valley, a setting that beautifully reflected the retreat’s core themes of renewal, mindfulness, and soul alignment.

Surrounded by rolling fields of lavender and the calming scent that filled the air, attendees were invited to slow down, breathe fully, and reconnect with both nature and themselves. The experience wove together mindful movement, gratitude practices, and moments of quiet joy. Each woman was guided through grounding exercises and intentional journaling designed to help release emotional burdens and open space for peace and clarity.

As participants explored the gardens and vineyard, laughter and sacred conversations filled the air. Many women described the visit as transformative, sharing that the blooming lavender fields mirrored their own journeys, learning how to bloom again after seasons of pruning and pain.

A Joyful and Symbolic Closing

The retreat concluded on Day Three with a stop at Buc-ee’s, symbolizing the truth that healing and happiness can be found in even the simplest, everyday moments.

After days of deep reflection and inner work, the final outing brought lightness, laughter, and celebration. Known for its welcoming spirit and sense of community, Buc-ee’s became more than a travel stop; it became a joyful celebration of presence, sisterhood, and shared purpose.

The experience closed with gratitude, embraces, and a collective sense of renewal, as each woman departed empowered and ready to align and rise into the next chapter of her life.

Partnerships, Purpose, and Continued Impact

In partnership with Blissful Life Consulting, the Align & Rise Retreat aligned with The Malaysia Harrell Foundation’s mission to empower and uplift Veteran women and women from underrepresented populations through holistic wellness, advocacy, and community support.

“This retreat perfectly embodied our mission: to create spaces where women feel seen, supported, and strengthened,” Harrell shared. “As we honored Veterans Day, we also honored the courage it takes to heal, rise, and live boldly in truth.”

The successful launch of Align & Rise marks a major milestone in The Malaysia Harrell Foundation’s growing legacy of mental health advocacy, spiritual empowerment, and community impact. Plans are already underway for the 2026 retreat, which will further expand access to holistic wellness experiences for Veterans and women nationwide.

Sponsors and Gratitude

The Align & Rise Retreat was made possible through the generous partnership of Moonstone Escape at the Gr8 Escapes in Virginia, Massanutten, a serene mountain sanctuary that offered the perfect backdrop for reflection, restoration, and reconnection.

The Malaysia Harrell Foundation extends heartfelt gratitude to its sponsors, Me Time Coffee, Target and Kira Dior Hair.

Each partner played a meaningful role in creating a retreat experience rooted in excellence, empowerment, and community. Their support demonstrated how purpose-driven brands can create transformation that extends far beyond a single event and into the lives and legacies of every woman who attended.

About The Malaysia Harrell Foundation

The Malaysia Harrell Foundation, Inc. is dedicated to empowering and uplifting Veteran women and women from underrepresented populations through holistic wellness, advocacy, and support. The foundation is committed to fostering resilience, healing, and personal growth while helping women reconnect with their purpose, embrace their strength, and live in alignment with their truth.

For the latest updates, connect with The Malaysia Harrell Foundation at:

Official website of Malaysia Harrell Foundation: https://malaysiaharrellfoundation.com

Email: malaysiaharrellfoundation@gmail.com

Instagram: https://www.instagram.com/malaysiaharrellfoundation/

Official website of Blissful Life Consulting: https://www.blissfullifeconsulting.com/

Media Contact
Company Name: Malaysia Harrell Foundation
Contact Person: Malaysia Harrell
Email:Send Email
City: Annapolis
State: Maryland
Country: United States
Website: malaysiaharrellfoundation.com

Why conservative private credit strategies matter more than ever

By Richard Woodhead, Founder and MD of one of Australia’s established private credit managers, GPS Investment Fund Limited

Over three decades of managing registered first mortgage investments through property booms, downturns, and recovery periods have reinforced one lesson: long-term investors benefit most when they focus on discipline rather than market noise. As private credit investments in Australia continue to grow, understanding conservative investing strategies is increasingly important for investors seeking stable, income-generating opportunities.

Private credit’s quiet expansion

The shift from traditional bank lending to non-bank alternatives has been ongoing. Tighter bank lending standards and a rising interest in secure investment options have contributed to this trend. For investors seeking yield and stability, mortgage funds backed by registered first mortgage security provide an asset-backed pathway into private credit investments in Australia.

Registered first mortgage investments typically place investors in a stronger position on the capital stack compared with mezzanine or second mortgage structures, though all investments carry risks. Conservative private credit strategies help manage these risks while offering a reliable alternative to more volatile asset classes.

Rethinking stability and income

Monthly income investments remain a cornerstone of many portfolios. The key considerations are how income is generated and how capital is protected. Conservative investment funds and property-backed strategies can deliver consistent results while helping manage risk.

When structured with:

Sound underwriting standards;

Moderate loan-to-value ratios; and

Careful regional market selection;

mortgage funds backed by registered first mortgage security can serve as effective alternatives to term deposits. However, investors should note that capital is not guaranteed, and all investments carry inherent risks.

Discipline, not expansion, defines longevity

Experience managing mortgage funds in Australia shows that stability is achieved through restraint and prudent risk management. Long-standing mortgage funds backed by registered first mortgage security often prioritize discipline over growth for growth’s sake, maintaining focus on transparency, regulatory compliance, and risk-aware lending practices.

Key principles of conservative registered first mortgage investing include:

Sound underwriting and borrower assessment;

Moderate loan-to-value ratios;

Regional and local market knowledge; and

Clear focus on transparency and regulatory compliance.

Past performance should not be taken as an accurate indicator of future results. Inestors must carefully assess their own risk tolerance before investing.

Media Contact
Company Name: Gpsinvest
Contact Person: Richard Woodhead
Email:Send Email
City: Sydney
Country: Australia
Website: https://gpsinvest.com.au/

Sabeer Nelli Leverages Industry Councils to Expand Payment Ecosystems

By blending the reach of industry councils with hands‑on mentorship, the Zil Money CEO is building a community of innovators—and delivering tangible benefits for small businesses

TYLER, TX, USA - November 22, 2025 - When Sabeer Nelli, CEO of Zil Money, first joined the Forbes Business Council, he didn’t just collect another accolade for his résumé. He saw it as an opportunity to meet emerging entrepreneurs, share hard‑won lessons, and discover new ways to improve financial tools for small businesses. Now, as a member of multiple influential councils—including Nacha’s Payments Innovation Alliance, the U.S. Faster Payments Council, FedNow Community Group and the Business Payments Coalition—he is proving that these networks can fuel real partnerships and mentorships.

Through his active role in industry councils, Sabeer Nelli works alongside bankers, regulators and fellow entrepreneurs to address systemic challenges. These formal collaborations often turn into co‑developed products: by partnering with new banks, he has expanded Zil Money’s network to more than 22 000 institutions, ensuring SMBs can transact through their existing accounts. He has also championed integrations with popular accounting platforms such as QuickBooks, Xero and Odoo, allowing businesses to sync bills and payments directly from the software they already rely on.

Beyond technology, Sabeer Nelli uses his council presence to support early‑stage innovators. He founded an accelerator program (ZilCubator) and hosts hackathons that provide capital, mentorship and access to resources. These initiatives feed into his broader vision of nurturing talent through a 30 000‑square‑foot tech hub, Silicon Jeri, that is already home to over 200 employees, creating a vibrant local ecosystem for innovation.

The mentorship goes both ways. Discussions about regulatory changes inform Zil Money’s roadmap and shape Sabeer Nelli’s advocacy efforts within payment councils. “Being surrounded by peers who challenge and inspire you keeps you sharp,” he noted. “It helps ensure that the solutions we build are not just innovative, but also fair and accessible.”

Sabeer Nelli is the founder and CEO of Zil Money Corporation. He previously built Tyler Petroleum into a multi‑million‑dollar enterprise before creating Zil Money to solve the payment problems he encountered.

LinkedIn: linkedin.com/in/sabeer-nelliparamban

Media Contact
Company Name: Sabeer Nelli
Contact Person: Sabeer Nelli
Email:Send Email
City: New York
Country: United States
Website: http://www.sabeer.com

The Leicester Locals Leading the Tax Refund Revolution

Pie Money Limited is a UK-based fintech company simplifying tax for individuals and small businesses. Its HMRC-approved platform helps users file tax returns, reclaim refunds and manage multiple income types with ease. With over 100,000 downloads, Pie is transforming the way the UK handles tax.

LEICESTER, United Kingdom - Leicester residents are increasingly turning to digital tax refund apps as they discover they may be missing out on hundreds of pounds in unclaimed rebates. From uniform costs to mileage, home-working expenses and professional fees, thousands of workers across the city are now reclaiming money they didn’t realise they were entitled to.

According to recent data from Pie, one of the UK’s fastest-growing tax platforms, Leicester has seen a surge in PAYE workers checking for missed refunds with many receiving £200–£400 back within days.

“Most people simply don’t know what they can claim,” said Tommy Mcnally, Founder of Pie. “Leicester’s workforce is busy, diverse and constantly on the go. A simple tax refund tool that explains everything clearly is exactly what people need and that’s why we’re seeing such rapid adoption.”

Why Leicester Workers Are Claiming More Money Back

Many PAYE employees in Leicester are unaware that everyday expenses can qualify for tax relief, including:

• Cleaning or replacing work uniforms

• Using personal vehicles for business mileage

• Professional memberships and union fees

• Tools, equipment and specialised work gear

• Home-working costs for hybrid roles

With living costs continuing to rise, workers are increasingly taking advantage of new digital tools that calculate entitlements and submit claims directly to HMRC.

Digital Tax Tools Fuel a Citywide Shift

Pie’s HMRC-compliant tax refund app has become especially popular among Leicester’s healthcare staff, retail workers, hospitality teams and logistics employees — sectors where uniform, travel and equipment costs are common.

The platform helps users:

• Check eligibility in minutes

• Automatically calculate their refund

• Submit securely to HMRC

• Track past years’ unclaimed expenses

Many Leicester workers have also discovered they can backdate claims for up to four years, unlocking larger refunds than expected.

Financial Empowerment for Everyday Workers

As more people across Leicester embrace financial technology for budgeting and savings, tax apps are becoming a natural next step offering transparency, speed and confidence in a process that has historically been confusing.

“People shouldn’t lose out on money they’re entitled to,” added Mcnally. “Our mission is to make tax simple for everyone, and Leicester is proving just how powerful that can be.”

Leicester locals who want to check if they’re owed a tax refund can get started today at https://pie.tax

About Pie

Pie Money Limited is a UK-based fintech company simplifying tax for individuals and small businesses. Its HMRC-approved platform helps users file tax returns, reclaim refunds and manage multiple income types with ease. With over 100,000 downloads, Pie is transforming the way the UK handles tax.

Media Contact: Pie Money Limited

help@pie.tax

https://pie.tax

Media Contact
Company Name: Pie Money Limited
Contact Person: Tommy Mcnally
Email:Send Email
Address:77 Lower Camden Street
City: Dublin 2
State: D02 XE80 Ireland
Country: United Kingdom
Website: https://pie.tax

Beauty+ Clinic Debut Face Injection Treatments: A Prophylactic Way to Keep Skin Glowing and Firm Without the Trouble

Face Injection Treatments

The majority of women nowadays are compelled to find time-efficient and smart skincare solutions as the hectic city life with full schedules of meetings and social activities hardly allows them to rest. In pursuit of such solutions, Beauty+ Clinic is proud to present its premium Face Injection treatments non-invasive aesthetic procedures designed to restore skin vitality and delay signs of aging, all without disrupting your schedule.

Jakarta, Indonesia - 20 November, 2025 - The majority of women nowadays are compelled to find time-efficient and smart skincare solutions as the hectic city life with full schedules of meetings and social activities hardly allows them to rest. In pursuit of such solutions, Beauty+ Clinic is proud to present its premium Face Injection treatments non-invasive aesthetic procedures designed to restore skin vitality and delay signs of aging, all without disrupting your schedule.

Face Injection is a medical aesthetic procedure that delivers active ingredients directly into the skin or subdermal layers to improve texture, contour, and hydration. Compared to surgical interventions, this treatment brings visible results almost immediately with only minimal downtime, thus, it is an excellent option for a long-term skin care solution without sacrificing a busy lifestyle.

“We are focusing on prevention rather than cure,” says the Medical Director of Beauty+ Clinic. “By doing less when more is needed—at the very first signs of fine lines or when skin is getting less elastic—we ensure our clients a longer period of youthful and radiant skin.”

Beauty+ Clinic offers the following Face Injection treatments like Collagen Biostimulator: Encourages collagen production in the skin leading to gradual and lasting firmness and smoother skin without the changes of facial expressions. Besides that, this procedure also enhances cellular regeneration which results in overall skin becoming more vibrant, brighter, and tougher from the inside.

Beauty+ Clinic takes pride in their safe, exact, and personalized approach that their team of professionals, each of whom is not only a certified medical practitioner but also has up to two decades of experience in aesthetic care, offers the patient.

About Beauty+ Clinic

Beauty+ Clinic stands out as an Indonesian aesthetic center setting high standards for itself by its thorough commitment to advanced skincare technologies and customization of treatment plans. By concentrating on prevention and yielding results as natural as possible, the clinic assures its customers the greatest pleasure, inner strength, and confidence, ultimately.

More info or scheduling of appointments can be done through a visit to the website https://beautyplusclinic.com or sending a message via WhatsApp to +62 812 1177 ​‍​‌‍​‍‌​‍​‌‍​‍‌2070.

Media Contact
Company Name: Beauty Plus Clinic
Contact Person: Mento Utoyo
Email:Send Email
Phone: +62 216596323
Address:Jl. Kerajinan Raya 38A Gajah Mada
City: Jakarta Pusat 11130
State: DKI JAKARTA
Country: Indonesia
Website: https://beautyplusclinic.com/

Pixazo Introduces Nano Banana Pro API, a Breakthrough in High-Fidelity Visual Generation

"Precision, consistency, and creative freedom are becoming essential in visual generation," said Abhinav Girdhar, Founder & CEO of Pixazo. "Nano Banana Pro delivers all three — empowering developers and creators to build richer, more dynamic visuals with remarkable reliability and speed."

Pixazo launches the Nano Banana Pro API, a next-generation image-to-image and visual generation model built on Gemini 3 Pro, offering advanced editing, multi-image synthesis, and high-fidelity character-consistent transformations.

NOIDA, Uttar Pradesh, India - November 21, 2025 - Pixazo today announced the release of its latest innovation in visual intelligence: the Nano Banana Pro API, a next-generation image-to-image and creative transformation technology built on Google’s powerful Gemini 3 Pro foundation. The launch marks a major advancement in Pixazo’s growing suite of professional-grade visual generation tools, offering creators and developers a new level of control, consistency, and fidelity in AI-driven imagery.

Nano Banana Pro significantly elevates the capabilities introduced by the original Nano Banana model, which became widely known for its stylistic accuracy and creative versatility. This new Pro version pushes the boundaries further, delivering exceptional performance in character-consistent editing, advanced scene modifications, and high-precision multi-image synthesis. Its ability to process multiple input images or characters within a single prompt enables seamless storytelling, complex compositions, and continuity-driven visual workflows.

Designed for both individual creators and enterprise-scale production, Nano Banana Pro excels at generating polished infographics, slide-style visuals, detailed transformations, and refined creative outputs optimized for campaign-ready assets. The model maintains stylistic coherence, identity accuracy, and high-resolution quality even in heavy customization scenarios — making it suitable for animation pipelines, brand design systems, product visualization, social content production, and advanced editing applications.

“Precision, consistency, and creative freedom are becoming essential in visual generation,” said Abhinav Girdhar, Founder & CEO of Pixazo. “Nano Banana Pro delivers all three — empowering developers and creators to build richer, more dynamic visuals with remarkable reliability and speed.”

By integrating Nano Banana Pro into the Pixazo ecosystem, users gain access to a unified interface that simplifies production workflows, regardless of complexity. The model’s performance is optimized for fast execution, enabling rapid iteration and high-volume generation without compromising artistic or technical quality.

About Pixazo

Pixazo (formerly Appy Pie Design) is a next-generation AI design and media creation platform under Appy Pie LLP. With products including the AI image generator, AI image-to-video generator, and AI meme creator, Pixazo empowers over 10 million users worldwide to design, animate, and innovate through artificial intelligence—making creativity fast, accessible, and limitless.

For more information, visit: https://www.pixazo.ai/

Media Contact
Company Name: Pixazo
Contact Person: Abhinav Girdhar
Email:Send Email
Country: India
Website: https://www.pixazo.ai/

Maryland Startup Swift Running Disrupts Performance Footwear Market with Affordable Carbon-Plated Technology

"Elite runners have had access to carbon-plated, ultra-lightweight performance shoes for years, but these technologies remained out of reach for everyday runners due to pricing. We launched Swift Running to change that—bringing the same advanced propulsion, cushioning, and durability technology to every runner, regardless of budget or experience level," said a spokesperson for Swift Running.

Swift Running, a Maryland-based footwear startup, is disrupting the performance running market with sub-7-ounce carbon-plated shoes priced far below major brands. With 150+ five-star reviews and rapid community growth, the company is proving premium technology can finally be accessible to every runner.

A Maryland-based startup is challenging the established order in performance running footwear with a simple but disruptive premise: advanced racing technology should be accessible to every runner, not just elite athletes with sponsorship deals. Swift Running, launched with a mission to democratize high-performance footwear, is proving that carbon-plated, ultra-lightweight shoes can be both technologically advanced and affordably priced.

The running shoe industry has undergone a technological revolution in recent years, with carbon fiber plates and advanced foam compounds delivering measurable performance benefits. However, these innovations typically debut at premium price points that place them beyond reach for many runners. Swift Running entered the market to close this accessibility gap, offering shoes with the same performance-enhancing features through a direct-to-consumer model that eliminates traditional retail markups.

Every Swift Running shoe incorporates the key technologies that define modern performance footwear. Carbon plates provide propulsion and energy return with each stride, while advanced cushioning systems protect joints during high-mileage training. Durability engineering ensures these performance benefits last through hundreds of miles. Most impressively, Swift Running achieves all this while keeping shoes under 8 ounces—a weight benchmark serious runners recognize as essential for speed and efficiency.

The company’s product philosophy reflects a deep understanding of how runners train. Rather than offering a single shoe type, Swift Running provides a full rotation that supports the entire training cycle. Their lineup includes daily trainers, distance trainers, tempo trainers, and recovery trainers—acknowledging that optimal performance requires different shoes for different purposes, and making a complete rotation financially attainable.

Since launching, Swift Running has earned more than 150 five-star product reviews, demonstrating consistent customer satisfaction with both quality and value. These reviews come from real runners putting Swift Running shoes through authentic training conditions—the most meaningful test any performance shoe can face. The brand’s growing community of 5,000 engaged social media followers offers ongoing feedback that directly informs product development.

Swift Running's commitment to community extends far beyond selling shoes. In just 12 months, the company has sponsored more than 50 running events across the Mid-Atlantic region and beyond—including charity races, high school track and cross-country meets, and partnerships with running clubs and fitness centers. This grassroots approach builds authentic relationships with runners while contributing to the growth and health of the sport.

The direct-to-consumer model Swift Running employs serves multiple strategic purposes. By selling through their website and Amazon Prime, the company eliminates traditional retail intermediaries and their associated markups. The resulting cost efficiency goes directly to customers through lower prices without compromising product quality or technology. The model also allows Swift Running to maintain close relationships with customers, gathering feedback and understanding needs more directly than traditional retail channels allow.

Swift Running’s target audience spans the entire spectrum of runners—from beginners taking their first steps toward fitness, to high school athletes chasing personal records, to marathoners working toward ambitious time goals. The company believes performance technology should serve every runner, not just the fastest or most experienced. Lightweight construction, proper cushioning, and carbon-plated propulsion benefit all athletes, and Swift Running ensures those benefits are no longer limited by budget.

Maryland’s location gives Swift Running a strategic advantage in product development. The Mid-Atlantic region hosts a thriving running culture, providing both a customer base and a real-world testing environment. The company’s deep local roots, reflected in its extensive event sponsorships, create lasting connections with the community while laying the groundwork for national expansion.

Looking ahead, Swift Running plans to broaden its product range with specialized track spikes, trail running shoes, and performance apparel. These additions will allow the company to offer comprehensive gear solutions while staying committed to its core mission: making elite performance technology accessible to all.

Swift Running's rapid growth and community enthusiasm underscore the market’s desire for a brand that delivers cutting-edge performance without the inflated price tag.

CONTACT

Discover Swift Running's performance footwear at https://www.swift-running.com/

Follow @swiftrunningus on Instagram, Facebook, TikTok, and YouTube

Media Contact
Company Name: Swift Running
Contact Person: John Watson
Email:Send Email
Country: United States
Website: https://www.swift-running.com/

Diabetic Macular Edema Pipeline Drugs Landscape Report 2025: MOA Analysis, R&D Progress, Clinical Trial Pipeline, and Strategic Market Evolution

DelveInsight's “Diabetic Macular Edema Pipeline Insight 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Diabetic Macular Edema Research. Learn more about our innovative pipeline today! @ Diabetic Macular Edema Pipeline Outlook

Key Takeaways from the Diabetic Macular Edema Pipeline Report

• On 10 November 2025, Genentech Inc. announced a study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab (in separate injections).
• On 03 November 2025, Bayer conducted a study is to learn if high-dose (8 mg) aflibercept given every 16 weeks works as well as low-dose (2 mg) aflibercept given every 8 weeks in Chinese participants. The study treatment, 8 milligram (mg) aflibercept is injected into the eye. It works by blocking a protein called vascular endothelial growth factor (VEGF) which causes abnormal growth and leakage of blood vessels at the back of the eye.
• DelveInsight’s Diabetic Macular Edema Pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Diabetic Macular Edema treatment.
• The leading Diabetic Macular Edema Companies such as Oculis, 4D Molecular Therapeutics, Ashvattha Therapeutics, Ocugen, AiViva BioPharma, Inc., Unity Biotechnology, Inc., Therini Bio Pty Ltd, Valo Health, Inc., Kyowa Kirin Co., Ltd., Invirsa, Inc., Frontera Therapeutics, EyePoint Pharmaceuticals, Inc., EyeBiotech Ltd., EnnovaBio, Eclipse Life Sciences, Inc., Merck & Co, Rezolute, Inc., Aviceda Therapeutics, KODIAK SCIENCES INC., AsclepiX Therapeutics and others.
• Promising Diabetic Macular Edema Pipeline Therapies such as Ranibizumab, Avastin (Bevacizumab), Ozurdex (dexamethasone), EXN407, IBE-814 70ug, Dexamethasone nanoparticles eye drops, EYP-1901 and others.

Discover groundbreaking developments in Diabetic Macular Edema therapies! Gain in-depth knowledge of key Diabetic Macular Edema Clinical Trials, emerging drugs, and market opportunities @ Diabetic Macular Edema Clinical Trials Assessment

The Diabetic Macular Edema Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Diabetic Macular Edema Pipeline Report also highlights the unmet needs with respect to the Diabetic Macular Edema.

Diabetic Macular Edema Overview

Diabetic macular edema (DME) is a common complication of diabetes that affects the macula, the central part of the retina responsible for sharp, detailed vision. It occurs when high blood sugar levels damage blood vessels in the retina, causing fluid leakage and swelling, leading to visual impairment. DME is one of the leading causes of blindness in adults, particularly in the United States. Early detection and treatment are crucial to prevent irreversible vision loss, with anti-vascular endothelial growth factor (VEGF) therapy currently being the standard of care. However, ongoing research is focused on developing new and more effective treatment options.

Diabetic Macular Edema Emerging Drugs Profile

• OCS-01: Oculis

OCS-01 is an innovative high concentration eye drop candidate to treat DME. It is developed with the proprietary OPTIREACH® technology to enable drug passage from the anterior to the posterior segment of the eye following topical application, a route of administration that contrasts with currently available DME therapies, all requiring invasive delivery to reach the retina, such as ocular implants or intravitreal injections. The OPTIREACH® solubilizing formulation technology addresses the main limitations of conventional eye drops by improving the solubility of lipophilic drugs, increasing the residence time on the eye surface and thereby enabling the drug passage from the eye surface to the posterior segment of the eye. Currently, the drug is in Phase III stage of its development for the treatment of Diabetic Macular Edema.

• 4D-150: 4D Molecular Therapeutics

4D-150 combines the customized and evolved intravitreal vector, R100, and a transgene cassette that expresses both aflibercept and a VEGF-C inhibitory RNAi. This dual-transgene payload inhibits four members of the VEGF angiogenic family of factors that drive wet AMD and DME: VEGF A, B, C and PlGF. R100 was invented at 4DMT through the proprietary Therapeutic Vector Evolution platform. 4D-150 is designed for single, low-dose intravitreal delivery for transgene expression from the retina without significant inflammation. Currently, the drug is in Phase II stage of its development for the treatment of Diabetic Macular Edema.

• D-4517.2: Ashvattha Therapeutics

D-4517.2 is a potent anti-angiogenic nanomedicine (“dendranib”) that crosses the blood-retinal barrier and selectively targets activated microglia, macrophages and retinal pigment epithelial cells in the eye. D-4517.2 has the potential to change the current treatment paradigm for neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME) by offering an at-home dosing option by a subcutaneous route of administration rather than delivery via intravitreal injection (injection into the eye). Currently, the drug is in Phase II stage of its development for the treatment of Diabetic Macular Edema.

• OCU200: Ocugen

OCU200 is a biologic product candidate in development for treating severely sight-threatening diseases like diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD). OCU200 is a novel fusion protein consisting of two human proteins, tumstatin and transferrin, that are already present in retinal tissues. OCU200 has unique features, which enable it to efficiently target leaky blood vessels, regress the existing abnormal blood vessels, and inhibit the growth of new blood vessels in the retina and choroid. Tumstatin, which acts as an anti-VEGF, anti-inflammatory, and anti-oxidative agent, is the active component of OCU200. It binds to integrin receptors, which play a crucial role in disease pathogenesis. Transferrin facilitates the targeted delivery of tumstatin into the retina and choroid and potentially helps increase the interaction between tumstatin and integrin receptors. Currently, the drug is in Phase I stage of its development for the treatment of Diabetic Macular Edema.

• AIV007: AiViva BioPharma, Inc.

AIV007 is a novel formulation using JEL™ Technology designed for prolonged drug release. AIV007 targets multiple pathways including VEGFR, PDGFR, and FGFR to address neovascularization and fibrosis, and it also modulates TGFβ1 mRNA expression and TGFβ1 levels to reduce collagen production and scarring. In nonclinical in vivo studies for nAMD, AIV007 demonstrated safety, efficacy, and prolonged treatment duration with a single intravitreal administration. Ocular safety and effects in the reduction of neovascularization and fibrosis were observed in several nonclinical animal models and patients. Currently, the drug is in Phase I stage of its development for the treatment of Diabetic Macular Edema.

Stay informed about the Diabetic Macular Edema pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Diabetic Macular Edema Unmet Needs

Diabetic Macular Edema Market Drivers

• Advances in Diabetic Macular Edema Treatment
• Improved Diagnostic Tools

Diabetic Macular Edema Market Barriers

• Diabetic Macular Edema Patient Adherence
• Side Effects and Safety Concerns associated Diabetic Macular Edema

The Diabetic Macular Edema Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Macular Edema with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Macular Edema Treatment.
• Diabetic Macular Edema Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Diabetic Macular Edema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Macular Edema market

Transform your understanding of the Diabetic Macular Edema Pipeline! See the latest progress in drug development and clinical research @ Diabetic Macular Edema Market Drivers and Barriers, and Future Perspectives

Diabetic Macular Edema Companies

Oculis, 4D Molecular Therapeutics, Ashvattha Therapeutics, Ocugen, AiViva BioPharma, Inc., Unity Biotechnology, Inc., Therini Bio Pty Ltd, Valo Health, Inc., Kyowa Kirin Co., Ltd., Invirsa, Inc., Frontera Therapeutics, EyePoint Pharmaceuticals, Inc., EyeBiotech Ltd., EnnovaBio, Eclipse Life Sciences, Inc., Merck & Co, Rezolute, Inc., Aviceda Therapeutics, KODIAK SCIENCES INC., AsclepiX Therapeutics and others.

Diabetic Macular Edema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Diabetic Macular Edema Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Diabetic Macular Edema Pipeline Report

• Coverage- Global
• Diabetic Macular Edema Companies- Oculis, 4D Molecular Therapeutics, Ashvattha Therapeutics, Ocugen, AiViva BioPharma, Inc., Unity Biotechnology, Inc., Therini Bio Pty Ltd, Valo Health, Inc., Kyowa Kirin Co., Ltd., Invirsa, Inc., Frontera Therapeutics, EyePoint Pharmaceuticals, Inc., EyeBiotech Ltd., EnnovaBio, Eclipse Life Sciences, Inc., Merck & Co, Rezolute, Inc., Aviceda Therapeutics, KODIAK SCIENCES INC., AsclepiX Therapeutics and others.
• Diabetic Macular Edema Pipeline Therapies- Ranibizumab, Avastin (Bevacizumab), Ozurdex (dexamethasone), EXN407, IBE-814 70ug, Dexamethasone nanoparticles eye drops, EYP-1901 and others.
• Diabetic Macular Edema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Diabetic Macular Edema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

"Stay Ahead in Endocrinology and Metabolic Disorders Research–Access the Full Diabetic Macular Edema Pipeline Analysis Today! @ Diabetic Macular Edema Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Diabetic Macular Edema: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diabetic Macular Edema– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. OCS-01: Oculis
9. Mid Stage Products (Phase II)
10. Early Stage Products (Phase I)
11. Preclinical and Discovery Stage Products
12. Drug Name: Company Name
13. Inactive Products
14. Diabetic Macular Edema Key Companies
15. Diabetic Macular Edema Key Products
16. Diabetic Macular Edema- Unmet Needs
17. Diabetic Macular Edema- Market Drivers and Barriers
18. Diabetic Macular Edema- Future Perspectives and Conclusion
19. Diabetic Macular Edema Analyst Views
20. Diabetic Macular Edema Key Companies
21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diabetic-macular-edema-pipeline-insight

Eczema Pipeline Drugs Landscape Report 2025: MOA Analysis, R&D Progress, Clinical Trial Pipeline, and Strategic Market Evolution

DelveInsight’s, “Eczema Pipeline Insight, 2025” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Eczema pipeline landscape. It covers the Eczema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Eczema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Eczema Pipeline. Dive into DelveInsight's comprehensive report today! @ Eczema Pipeline Outlook

Key Takeaways from the Eczema Pipeline Report

• On 17 November 2025, Inmagene LLC conducted a phase 2b study to assess the efficacy and safety profile of various dose regimens of IMG-007 in adult participants with moderate-to-severe active atopic dermatitis (AD) up to 52 weeks.
• On 14 November 2025, Celldex Therapeutics announced a phase 2 study to assess the efficacy and safety of barzolvolimab (CDX-0159) in adult participants with Atopic Dermatitis. There is a screening period of up to 28 days, a 16-week double-blind, placebo-controlled treatment period, a 16-week double-blind, active treatment period, and a 16-week follow-up period. On Day 1, participants will be randomly assigned on a 1:1:1 ratio to receive barzolvolimab (CDX-0159) by subcutaneous injections of 150 mg every 4 weeks (Q4W) after an initial loading dose of 450 mg [Arm 1], 300 mg Q4W after an initial loading dose of 450 mg [Arm 2], or placebo Q4W [Arm 3].
• On 10 November 2025, Aclaris Therapeutics Inc. initiated a study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
• DelveInsight’s Eczema pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Eczema treatment.
• The leading Eczema Companies such as Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
• Promising Eczema Pipeline Therapies such as alitretinoin, Arctiva, KY1005, Dupilumab, Lebrikizumab, Baricitinib, MEDI9929, Midazolam, Omeprazole, and others.

Stay ahead with the most recent pipeline outlook for Eczema. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Eczema Treatment Drugs

The Eczema Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Eczema Pipeline Report also highlights the unmet needs with respect to the Eczema.

Eczema Overview

Eczema, also known as atopic dermatitis, is the most common form of dermatitis. Genetic as well as environmental factors are thought to play a part in the pathogenesis. Eczema is most commonly seen in children but can be seen in adults. People with the disease tend to have dry, itchy skin that is prone to infection. Eczema is commonly known as the ""itch that rashes"" due to dry skin that leads to a rash as a result of scratching or rubbing. The most important treatment of eczema is skin hydration followed by topical steroids for flare-ups. The lifetime prevalence of atopic dermatitis is about 15-30% in children and 2-10% in adults.

Eczema Emerging Drugs Profile

• Amlitelimab: Kymab

Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczema.

• BX 005: BiomX

BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

• LP 0145: LEO Pharma

LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczemas.

The Eczema Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Eczema with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Eczema Treatment.
• Eczema Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Eczema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Eczema market

Explore groundbreaking therapies and clinical trials in the Eczema Pipeline. Access DelveInsight's detailed report now! @ New Eczema Drugs

Eczema Companies

Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.

Eczema Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Eczema Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Unveil the future of Eczema Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Eczema Market Drivers and Barriers

Scope of the Eczema Pipeline Report

• Coverage- Global
• Eczema Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
• Eczema Pipeline Therapies- alitretinoin, Arctiva, KY1005, Dupilumab, Lebrikizumab, Baricitinib, MEDI9929, Midazolam, Omeprazole, and others.
• Eczema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Eczema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Eczema Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Eczema Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Eczema: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Eczema– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Amlitelimab: Kymab
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Eczema Key Companies
21. Eczema Key Products
22. Eczema- Unmet Needs
23. Eczema- Market Drivers and Barriers
24. Eczema- Future Perspectives and Conclusion
25. Eczema Analyst Views
26. Eczema Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/eczema-pipeline-insight